Staphylococcus Aureus Decolonization Study (SuDS)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Stephanie A. Fritz, Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT00731783
First received: August 7, 2008
Last updated: April 23, 2012
Last verified: April 2012
Results First Received: March 2, 2011  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Staphylococcal Skin Infections
Abscesses
Furunculosis
Staphylococcus Aureus
MRSA Infection
Interventions: Drug: 2% Mupirocin Ointment
Drug: 4% Chlorhexidine liquid soap
Behavioral: Hygiene protocol

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Index Patient Only Only the child recently treated for a skin or soft tissue infection will undergo the decolonization regimen, which includes application of 2% Mupirocin Ointment to the anterior nares twice daily for 5 days and washing with 4% Chlorhexidine liquid soap daily for 5 days.
Household All members of the household (over the age of 6 months) will be asked to follow the study protocol, which includes application of 2% Mupirocin Ointment to the anterior nares twice daily for 5 days and washing with 4% Chlorhexidine liquid soap daily for 5 days.

Participant Flow for 4 periods

Period 1:   One Month Follow-Up Visit
    Index Patient Only     Household  
STARTED     92     91  
COMPLETED     78     69  
NOT COMPLETED     14     22  
Lost to Follow-up                 14                 22  

Period 2:   Three Month Follow-Up Visit
    Index Patient Only     Household  
STARTED     79     73  
COMPLETED     72     57  
NOT COMPLETED     7     16  
Lost to Follow-up                 7                 16  

Period 3:   Six Month Follow-Up Visit
    Index Patient Only     Household  
STARTED     77     67  
COMPLETED     71     64  
NOT COMPLETED     6     3  
Lost to Follow-up                 6                 3  

Period 4:   12 Month Follow-Up Visit
    Index Patient Only     Household  
STARTED     74     65  
COMPLETED     68     58  
NOT COMPLETED     6     7  
Lost to Follow-up                 6                 7  



  Baseline Characteristics
  Hide Baseline Characteristics

Reporting Groups
  Description
Index Patient Only Only the child recently treated for a skin or soft tissue infection will undergo the decolonization regimen.
Household All members of the household (over the age of 6 months) will be asked to follow the study protocol.
Total Total of all reporting groups

Baseline Measures
    Index Patient Only     Household     Total  
Number of Participants  
[units: participants]
  92     91     183  
Age  
[units: Years]
Mean ± Standard Deviation
  6.3  ± 5.7     5.7  ± 6.0     6.0  ± 5.8  
Gender  
[units: Participants]
     
Female     55     51     106  
Male     37     40     77  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Index Patients Eradicated of S. Aureus Carriage - 1 Month After Performing Decolonization Measures   [ Time Frame: 1 month after enrollment. ]

2.  Secondary:   Number of Index Patients Eradicated of S. Aureus Carriage - 3 Month After Performing Decolonization Measures   [ Time Frame: 3 month after enrollment. ]

3.  Secondary:   Number of Index Patients Eradicated of S. Aureus Carriage - 6 Month After Performing Decolonization Measures   [ Time Frame: 6 month after enrollment. ]

4.  Secondary:   Number of Index Patients Eradicated of S. Aureus Carriage - 12 Month After Performing Decolonization Measures   [ Time Frame: 12 month after enrollment. ]

5.  Secondary:   Recurrence of CA-MRSA Skin or Soft Tissue Infection - 1 Month After Enrollment.   [ Time Frame: 1 month after enrollment ]

6.  Secondary:   Recurrence of CA-MRSA Skin or Soft Tissue Infection - 3 Month After Enrollment.   [ Time Frame: 3 month after enrollment ]

7.  Secondary:   Recurrence of CA-MRSA Skin or Soft Tissue Infection - 6 Month After Enrollment.   [ Time Frame: 6 month after enrollment ]

8.  Secondary:   Recurrence of CA-MRSA Skin or Soft Tissue Infection - 12 Month After Enrollment.   [ Time Frame: 12 month after enrollment ]


  Serious Adverse Events


  Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Stephanie A. Fritz, M.D., M.S.C.I.
Organization: Washington University
phone: 314-454-6050
e-mail: fritz_s@kids.wustl.edu


No publications provided by Washington University School of Medicine

Publications automatically indexed to this study:

Responsible Party: Stephanie A. Fritz, Washington University School of Medicine
ClinicalTrials.gov Identifier: NCT00731783     History of Changes
Other Study ID Numbers: 3177 38145
Study First Received: August 7, 2008
Results First Received: March 2, 2011
Last Updated: April 23, 2012
Health Authority: United States: Institutional Review Board